MannKind Corp. said on May 18 that the FDA will review the application for its experimental inhaled insulin Afresa. MannKind is seeking approval for the drug"s use in type 1 or type 2 diabetics to control high blood sugar levels. The agency’s acceptance of the application comes after a few large drugmakers, like Pfizer, have stopped looking to create such treatments due to weak demand and safety concerns.